H.C. Wainwright lowered the firm’s price target on Greenwich LifeSciences to $36 from $38 and keeps a Buy rating on the shares after the company provided an update on the Phase 3 FLAMINGO-01 trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GLSI:
